FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma

Plasmacytoma can be confined to bone (solitary bone plasmacytoma) or occur in extramedullary sites (extramedullary plasmacytoma).[1][1]–[4][2] Diagnostic criteria are a biopsy-proven lesion of bone or soft tissue with evidence of clonal plasma cells, normal bone marrow with no evidence of clonal

[1]  D. Shin,et al.  Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy , 2006, The Korean journal of internal medicine.

[2]  A. Dispenzieri,et al.  Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[3]  U. Metser,et al.  Fatal interstitial pneumonitis related to rituximab-containing regimen. , 2006, Clinical lymphoma & myeloma.

[4]  C. Nanni,et al.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  H. Ghesquières.  Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  T. Naoe,et al.  A Case of Interstitial Pneumonia Induced by Rituximab Therapy , 2005, International journal of hematology.

[7]  Rafael J Leon,et al.  Rituximab-induced acute pulmonary fibrosis. , 2004, Mayo Clinic proceedings.

[8]  J. Dutcher,et al.  Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.

[9]  R. Kaczmarski,et al.  Interstitial pneumonitis related to rituximab therapy. , 2003, The New England journal of medicine.

[10]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[11]  A. Waxman,et al.  Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Cox,et al.  Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone , 2002, Cancer.

[13]  H. Döhner,et al.  Initial results in the assessment of multiple myeloma using 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  M. Dimopoulos,et al.  Solitary plasmacytoma of bone and extramedullary plasmacytoma. , 1999, Hematology/oncology clinics of North America.

[15]  M. Dimopoulos,et al.  Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Dimopoulos,et al.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma. , 1992, Hematology/oncology clinics of North America.

[17]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[18]  R. Fanin,et al.  A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography , magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma , 2007 .

[19]  B. Ko,et al.  Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma. , 2007, Haematologica.

[20]  F. Peyrade,et al.  [Alveolar hypoxemic interstitial pneumonia related to rituximab therapy]. , 2004, Revue des maladies respiratoires.

[21]  J. Byrd,et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.

[22]  N. Sobol,et al.  PRELIMINARY RESULTS , 2004 .